Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H PALMER

Showing results (1021-1030 of 1,033) with videos related to

Pageof 104
Sort By:
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
British Journal of Cancer|March 9, 2018
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancerN O Elander, K Aughton, P Ghaneh, et al.
Molecular Biology and Evolution|May 18, 2021
Analysis of Genomic DNA from Medieval Plague Victims Suggests Long-Term Effect of Yersinia pestis on Human Immunity GenesAlexander Immel, Felix M Key, András Szolek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Pageof 104

Showing results (1021-1030 of 1,033) with videos related to

Sort By:
Pageof 104
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
JAMA|September 9, 2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJohn P Neoptolemos, Deborah D Stocken, Claudio Bassi, et al.
The Lancet. Oncology|March 30, 2019
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 studyJohn N Primrose, Richard P Fox, Daniel H Palmer, et al.
British Journal of Cancer|March 9, 2018
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancerN O Elander, K Aughton, P Ghaneh, et al.
Molecular Biology and Evolution|May 18, 2021
Analysis of Genomic DNA from Medieval Plague Victims Suggests Long-Term Effect of Yersinia pestis on Human Immunity GenesAlexander Immel, Felix M Key, András Szolek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2024
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III TrialDaniel H Palmer, Richard Jackson, Christoph Springfeld, et al.
Lancet (London, England)|January 29, 2017
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialJohn P Neoptolemos, Daniel H Palmer, Paula Ghaneh, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
Pageof 104